The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Goddard Colin since 2006.
The trader's CIK number is 1225199.
At the time of the last reporting, Goddard Colin was the Chief Executive Offi of Human Genome Sciences Inc. (stock ticker symbol HGSI).
Also see all insider trading activities at Human Genome Sciences Inc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2010 | OSIP | 0 | $0 | 66,000 | $3,641,220 | 66,000 | $1,534,500 |
| 2007 | OSIP | 0 | $0 | 41,000 | $1,523,396 | 41,000 | $281,875 |
| 2006 | OSIP | 0 | $0 | 54,000 | $1,804,277 | 54,000 | $452,250 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2011 | HGSI | 5,726 | $123,237 | 0 | $0 | 0 | $0 |
1. Osi Pharmaceuticals Inc (OSIP)
2. Human Genome Sciences Inc (HGSI)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2010-03-01 | OSIP | Option Ex | 66,000 | 23.25 | 1,534,500 |
| 2010-03-01 | OSIP | Sale | 66,000 | 55.17 | 3,641,220 |
| 2007-06-04 | OSIP | Option Ex | 41,000 | 6.88 | 281,875 |
| 2007-06-04 | OSIP | Sale | 41,000 | 37.16 | 1,523,396 |
| 2006-08-25 | OSIP | Option Ex | 30,000 | 7.88 | 236,250 |
| 2006-08-25 | OSIP | Sale | 27,250 | 36.04 | 982,008 |
| 2006-08-25 | OSIP | Sale | 2,750 | 36.32 | 99,869 |
| 2006-06-02 | OSIP | Option Ex | 24,000 | 9.00 | 216,000 |
| 2006-06-02 | OSIP | Sale | 24,000 | 30.10 | 722,400 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2011-08-04 | HGSI | Buy | 3,000 | 16.17 | 48,510 |
| 2011-03-22 | HGSI | Buy | 2,726 | 27.41 | 74,727 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Goddard Colin (Chief Executive Offi of Human Genome Sciences Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.